4/A//SEC Filing
Baldry Mark 4/A
Accession 0001628280-25-029113
CIK 0001501697other
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 5:01 PM ET
Size
5.5 KB
Accession
0001628280-25-029113
Insider Transaction Report
Form 4/AAmended
Baldry Mark
Chief Commercial Officer
Transactions
- Award
Common Stock
2025-05-16$2.48/sh+1,032$2,561→ 25,337 total
Footnotes (1)
- [F1]On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share. Such transaction was exempt under both Rule 16b-3(d) and Rule 16b-3(c) of the Securities Exchange Act of 1934, as amended.
Documents
Issuer
X4 Pharmaceuticals, Inc
CIK 0001501697
Entity typeother
Related Parties
1- filerCIK 0001644137
Filing Metadata
- Form type
- 4/A
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 5:01 PM ET
- Size
- 5.5 KB